← Perrigo Company plc (PRGO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Perrigo Company plc (PRGO)
Pharmaceutical Preparations · market cap $2.0B · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Perrigo Company plc (PRGO) is a large-scale private-label OTC pharmaceutical manufacturer, Irish-domiciled for tax purposes, with $4.25B in 2025 revenue and a market cap of ~$1.48B. The company carries a substantial $3.28B net debt load against only $357M cash (~9 months runway), and posted a $1.43B net loss in 2025. Its pipeline is thin — the lead clinical asset is a Phase 3 study of pseudoephedrine HCl 30mg tablets for nasal congestion, a well-understood OTC molecule.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| pseudoephedrine hydrochloride 30 mg tablets | Phase 3 | Nasal Congestion Associated With the Common Cold |
Price & technical context
3-month
+29.8%
6-month
+32.6%
12-month
-36.1%
52-wk range
$9.25–$22.51
vs 50-day MA
+7.7%
vs 200-day MA
+17.1%
Realized vol
56.5%
Max drawdown
-68.6%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PRGO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.